Bemetson

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bemetson

What is Bemetson? (Overview)

Property Description
Active ingredient Betamethasone Dipropionate
Form Topical preparations (cream, ointment, lotion, gel)
Pharmacological class Glucocorticoid (High/Super-High Potency Corticosteroid)
General Purpose To suppress local inflammation, redness, and itching
Origin Synthetic analog

Bemetson: A Highly Potent Topical Corticosteroid

Bemetson is a pharmaceutical preparation defined by its active ingredient, Betamethasone Dipropionate, and is classified within the pharmacological class of glucocorticoids. The medicine’s core identity is that of a synthetic steroid ester and a fluorinated corticosteroid, designed for local application on the skin. This preparation is a synthetic analog of naturally occurring steroid hormones, chemically modified to enhance its therapeutic action and potency for dermatological use.

As a topical corticosteroid, Betamethasone Dipropionate is categorized by its super-high potency rating, a characteristic that differentiates it from lower-strength options like hydrocortisone. Topical corticosteroids are fundamental in managing inflammatory skin conditions due to their ability to rapidly reduce inflammation. The use of the dipropionate ester form specifically allows for enhanced lipid solubility, which facilitates a high percutaneous absorption rate through the skin barrier.

Composition and Forms: What Makes up the Preparation?

Bemetson consists of the active substance, Betamethasone Dipropionate, which is incorporated into various topical preparations such as a cream, an ointment, a gel, or a lotion. The preparation is typically manufactured as a single-agent product, focusing the treatment on the concentrated action of the corticosteroid.

The physical form, or vehicle, is essential because it determines how the active ingredient interacts with the skin. For example, the use of an occlusive ointment base (often containing mineral oil and petrolatum) can create an augmented formulation that maximizes absorption and strength. This feature is utilized for treating thick, dry patches of skin. The variety of available forms allows the medication to be matched to the specific characteristics of the skin area being treated.

General Purpose: Why Use a Glucocorticoid on the Skin?

The general purpose of Bemetson is to provide potent relief from the intense irritation, redness, and itching associated with localized skin inflammation. Its classification as a glucocorticoid means it possesses strong anti-inflammatory and localized immunosuppressive properties, which are the primary actions required to stabilize skin tissue. This medication is typically employed when severe inflammation or persistent itching requires a forceful suppression of the localized immune response.

Regulatory References

  1. Betamethasone Dipropionate
  2. Glucocorticoids
  3. Topical Betamethasone
  4. Betamethasone Dipropionate Potency Classification

What side effects are possible with Bemetson?

Possible Side Effects and Safety Information: Bemetson

Bemetson (betamethasone) is a potent corticosteroid with an established safety profile documented by regulatory authorities. Its use is associated with two primary systemic risks identified in hazard classification: Reproductive Toxicity and Specific Target Organ Toxicity (STOT) from Repeated Exposure.


Key Adverse Reactions and Systemic Risks

Classification/Category Details/Affected System Safety Restriction Context
Reproductive Toxicity May damage the unborn child Special handling instructions and precautions are required for women of childbearing potential.
STOT - Repeated Exposure Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland Risk is explicitly associated with prolonged use; regulatory bodies mandate discontinuation when clinical control is achieved.
Ophthalmic Reactions Increased risk of cataracts, glaucoma, and increased intraocular pressure Strict precautions to avoid contact with the eyes.
Local Dermatological Reactions Stinging, burning, itching, skin atrophy, telangiectasia, bruising, hypopigmentation These are commonly reported reactions at the application site, particularly in children.

Safety Monitoring and Limitations

Systemic absorption of Bemetson can lead to reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, particularly with prolonged use, high potency formulations, or application to large surface areas. This requires monitoring for potential glucocorticosteroid insufficiency, especially upon withdrawal of treatment.

Use of Bemetson (e.g., augmented cream) is formally limited by the FDA and other agencies to no more than 50 grams per week to mitigate systemic risk. It is also advised to avoid use on the face, groin, underarms, or if thinning of the skin is already present, due to heightened risk of local adverse reactions in these areas. For all formulations, the product is strictly for topical use and must not be used orally, ophthalmically, or intravaginally.

Overdose and Emergency Response

Overdose and When to Seek Emergency Help

This information pertains to accidental ingestion or excessive exposure to Bemetson (betamethasone) topical preparations.


Immediate Emergency Action

If Bemetson topical medication has been swallowed, or if there is excessive exposure, seek emergency medical attention immediately.

  • For Ingestion: Contact a poison control center right away for advice. In the U.S., the Poison Help line is 1-800-222-1222.
  • For Severe Symptoms: If the person has collapsed, has difficulty breathing, or cannot be awakened, call local emergency services (911 in the U.S.) immediately.

Overdose Context and Potential Effects

Overdose or toxicity is primarily associated with accidental ingestion of the topical product. When swallowed, topical corticosteroids typically cause mild symptoms, often limited to minor upset stomach or diarrhea, though medical guidance should always be sought.

Overuse of topical corticosteroids, especially over large areas of the body or for prolonged periods, increases the risk of the medication being absorbed into the bloodstream. This systemic absorption can lead to a condition where the adrenal glands are suppressed. Children are at an increased risk for such systemic effects, which can include signs like slowed growth or delayed weight gain. The risk is also elevated when the product is used under occlusive dressings or on areas like the face or skin folds.

Symptoms that may indicate significant absorption or systemic effect include blurred vision, dizziness, fast heartbeat, increased thirst or urination, or unusual tiredness. Any sudden onset of severe rash, redness, swelling, or signs of a skin infection in the treated area also requires immediate medical evaluation.

Therapeutic Uses of Bemetson

What Bemetson treats: main uses and benefits

The therapeutic role of Bemetson is relevant in contexts involving heightened systemic burden and inflammatory or irritative states. In clinical application, it is commonly used across conditions presenting with acute episodes where supportive symptom management is appropriate. The medication is applied across domains where additional symptomatic support is needed to address symptoms that become more disruptive during flare-ups.

It is generally used for managing symptoms associated with inflammatory skin disorders, like eczema, dermatitis, and psoriasis, and is also applied in managing systemic inflammatory conditions such as severe arthritis and allergic reactions. This broad use profile indicates that the medication plays a role in managing a range of symptoms.

“This supportive relief may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress.”

The key benefit is that it helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations. This contributes to easing the overall symptom load and improving day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Inflammatory Symptoms Bemetson is commonly used to help manage symptoms related to inflammatory or irritative states that manifest as pronounced swelling, redness, and severe itching, applied in scenarios where additional management of discomfort is required.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Bemetson (Topical)

The official regulatory labeling for Bemetson (topical betamethasone) defines who can and cannot use the medicine, focusing on managing the risk of systemic absorption and avoiding use on inappropriate conditions.

Population Category Regulatory Status (Official)
Absolute Contraindication Patients with known hypersensitivity to betamethasone or any component. Infants under one year of age (due to high systemic risk).
Conditional Use Only Children le 12 years (limited use to minimum effective amount, no occlusion, close monitoring for HPA axis suppression). Pregnant or lactating women (use only if benefit outweighs risk; avoid extensive use).
Contraindicated Conditions Rosacea, acne vulgaris, perioral dermatitis, or untreated cutaneous infections (bacterial, fungal, viral).
Caution Required Patients with liver impairment or those using on large areas of skin or under occlusion (increased risk of systemic side effects).

Use is established for adults and generally permitted for children over one year (or 13 years for some higher-potency forms), but always under strict limitations due to the potential for systemic absorption, which is heightened in children. The medicine is not to be used to treat certain conditions or on specific sensitive areas like the face or eyelids.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bemetson, as a topical glucocorticoid, has a documented interaction profile driven by potential systemic absorption, leading to specific pharmacokinetic and pharmacodynamic interactions with co-administered medicines, as outlined in regulatory documentation.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Product Category Type of Interaction and Outcome Interaction Restriction
Other Corticosteroids (Topical or Systemic) Exposure-Modifying (Additive systemic effect). Increases total glucocorticoid exposure; raises risk of HPA axis suppression and Cushing’s syndrome manifestations. Use is generally restricted due to the increased risk of cumulative systemic effects.
Hepatic Enzyme Inducers (e.g., Phenytoin, Rifampicin) Pharmacokinetic (Increased metabolic clearance). May reduce Bemetson plasma concentrations and decrease its intended therapeutic effect. Monitoring may be required.
Potassium-Depleting Diuretics (e.g., Furosemide) Pharmacodynamic (Electrolyte imbalance). Increased risk of hypokalaemia, which can heighten the toxicity of cardiac glycosides like Digitalis. Close electrolyte monitoring is necessary.
Anti-diabetic agents Pharmacodynamic (Glucose level alteration). May increase blood glucose levels, potentially requiring adjustment of anti-diabetic medication dosage. Blood glucose monitoring is required.

Interaction-Related Restrictions

Administration of live virus vaccines is formally contraindicated during Bemetson treatment due to immunosuppressive concerns. Additionally, the risk of gastrointestinal bleeding is increased when Bemetson is used concomitantly with Aspirin or Non-Steroidal Anti-inflammatory Drugs (NSAIDs), especially in patients with certain clotting factor deficiencies.

Population-Dependent Cautions

Official labeling notes that the interaction risk for systemic toxicity is increased in pediatric patients (due to a higher skin surface area to body mass ratio) and in patients with liver failure (due to reduced drug clearance).

Mechanism of Action

Intracellular Targeting and Transcriptional Modulation

The active ingredient, Betamethasone Dipropionate, functions as an agonist of the intracellular Glucocorticoid Receptor ( GR). The drug-receptor complex translocates into the cell nucleus to alter gene expression. This alteration occurs through two primary actions: transrepression, which blocks pro-inflammatory transcription factors like NF-kappa B, and transactivation, which promotes the synthesis of anti-inflammatory proteins. This genomic mechanism is required to initiate a modification in cellular signaling that alters subsequent physiological output.

Indirect Enzymatic Blockade and Vasoconstrictive Activity

By promoting the synthesis of Lipocortin-1, the drug indirectly and functionally inhibits the enzyme Phospholipase A2 ( PLA2). This PLA2 blockade halts the release of arachidonic acid, thereby suppressing the creation of mediators like prostaglandins and leukotrienes. Concurrently, the molecule induces local vasoconstriction (narrowing of blood vessels). These physiological consequences—reduced immune signaling, diminished cellular infiltration, and restricted blood flow—collectively function to modulate the biological processes associated with local inflammation.

Dosage and Administration Information

Instructions for Using Bemetson (Betamethasone Dipropionate 0.05%)

The usage of Bemetson topical preparations is characterized by specific parameters to ensure proper administration. This medicine is defined for external use only and is specifically not for oral, ophthalmic (eye), or intravaginal use.

Usage Parameter Guidelines
Route of Administration Topical (Dermatologic use only)
Dosing Schedule Apply a thin film to the affected area once or twice daily.
Maximum Dose Should not exceed 50 g per week for high-potency formulations.
Treatment Duration Limit continuous therapy to no more than 2 consecutive weeks.

Procedural Administration Constraints

The preparation is typically gently and thoroughly massaged into the skin. Therapy is discontinued when control is achieved, and if a dose is missed, treatment is resumed with the next scheduled application.

The medication is not used with occlusive dressings (such as bandages or wraps) unless explicitly directed by a healthcare professional, as occlusion can significantly increase absorption. Application is avoided on sensitive areas, including the face, groin, and axillae (armpits). For pediatric patients, use in children under 13 years of age is generally not recommended for high-potency augmented formulations, and treatment is administered in the minimum quantity for the shortest duration compatible with benefit.

These parameters collectively establish a duration-limited and quantity-limited use protocol for Bemetson, defining the standardized approach for its administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bemetson

Evidence for Use in Inflammatory Skin Conditions

Bemetson (Betamethasone Dipropionate) was studied for conditions characterized by fluctuating or episodic manifestations on the skin, such as severe eczema and other inflammatory and irritative states for which corticosteroids are studied. The main evidence comes from numerous short-term Randomized Controlled Trials (RCTs) and regulatory clinical trials, which involved evaluating different Bemetson formulations against a non-active substance (known as a vehicle). These studies enrolled adult participants and generally focused on measuring changes in visible signs like redness, scaling, and skin thickness, as well as the intensity of itching.

The trials was studied for short-term symptom patterns, typically over a period of two to four weeks. Findings describe patterns observed in the studies where measurements were taken of outcomes related to physical discomfort and skin inflammation severity according to standardized ratings, like the Physician Global Assessment (PGA). Research provides insight into short-term changes in these outcomes linked to inflammatory or irritative states.

Studies on Plaque Psoriasis

Phase 3 clinical trials were conducted in adults with mild to moderate chronic plaque psoriasis. In these trials, studies explored outcomes related to physical discomfort by monitoring symptom scores using validated tools like the Psoriasis Area and Severity Index (PASI) and the PGA score.

Findings describe patterns observed in the studies showing how the measured severity of plaques was monitored over the defined time intervals, usually four to eight weeks. Research highlights the proportion of participants who reached predefined clinical endpoints, such as the status described as “clear” or “almost clear” skin, as measured during the study period.

Research in Atopic Dermatitis (Eczema)

For atopic dermatitis (eczema), research was observed in both adult and pediatric populations. A significant portion of the research, particularly in younger children, focused on monitoring systemic absorption, which involved assessing the Hypothalamic-Pituitary-Adrenal (HPA) axis, a method for outcomes monitoring physiological strain or stress. Findings indicate that systemic absorption may be higher in younger children than in adults.

What Remains Uncertain About Bemetson Evidence

Despite the evidence level being graded as High for short-term symptom patterns, several important areas are not fully established in the research landscape. A key gap relates to the limited information for long-term outcomes. The follow-up durations were limited in nearly all pivotal studies, making it difficult to fully understand the long-term patterns observed in the studies regarding flare-ups, chronic disease management, or durability of the changes measured. Furthermore, the evidence was primarily based on comparisons to a non-active substance (vehicle); therefore, comparative evidence against other active treatments is uncertain.

Key Studies & References

  1. Betamethasone Dipropionate Cream USP, 0.05% (Potency expressed as betamethasone) - DailyMed (FDA Labeling)
  2. Betamethasone Dipropionate Gel (Augmented), 0.05% - DailyMed (FDA Labeling)

Frequently Asked Questions (FAQ)

Common questions about Bemetson (FAQ)

Q: Does Bemetson treat the root cause of a condition or only the symptoms?

According to official documents, Bemetson's primary purpose is to suppress the local symptoms of inflammation, such as redness, itching, and swelling. As a powerful corticosteroid, it works at a cellular level to modulate the inflammatory response and immune function. Its effect is focused on symptom management, as opposed to curing the underlying condition.


Q: What are the main differences between Bemetson and other medications for the same condition?

Bemetson (Betamethasone Dipropionate) is classified as a super-high potency topical corticosteroid. The differences compared to other medications in its class are mainly determined by the type of corticosteroid salt and the formulation vehicle used. These factors directly affect the strength and absorption of the medicine through the skin.


Q: Is it normal to feel a mild headache after starting Bemetson?

Headache is one of the adverse reactions that has been reported with corticosteroids. It is more likely to occur if enough medication is absorbed into the bloodstream. If systemic symptoms such as a persistent headache are experienced, it is important to seek advice from a healthcare professional.


Q: Does Bemetson have any known effects on appetite or body weight?

Since Bemetson is a corticosteroid, there is a rare possibility of systemic absorption, especially when applied to large areas or for a long time. In such cases, effects commonly seen with oral steroids, such as increased appetite and weight gain, may potentially occur.


Q: Can Bemetson cause changes in mood or sleep patterns?

The risk of systemic absorption means Bemetson could rarely lead to changes in mood or sleep, similar to other medications in the corticosteroid class. These effects might include emotional changes, irritability, or difficulty sleeping.


Q: Are there any specific supplements that are known to interact with Bemetson?

Official regulatory information on the specific interactions between Bemetson and herbal remedies, vitamins, or dietary supplements is limited. Official information suggests informing a healthcare professional about all non-prescription products being used.


Q: Are there any known food restrictions or dietary interactions when using Bemetson?

Topical Bemetson does not have mandatory food restrictions. However, because corticosteroids can potentially affect sodium and potassium levels in the body if absorbed systemically, dietary adjustments may be considered by a healthcare professional in certain medical circumstances to help manage electrolyte balance.


Q: Are the safety considerations the same for all known formulations of Bemetson?

No, the safety considerations are not the same across all formulations. The potency of Bemetson and its risk of systemic absorption vary significantly based on the preparation (such as a cream, ointment, or augmented formulation). Higher-potency forms generally require stricter usage limitations.


Q: Is Bemetson known to affect male or female fertility?

Official regulatory reviews indicate there is no evidence suggesting that topical Bemetson (Betamethasone Dipropionate) affects fertility in either men or women.


Q: Is Bemetson known to lose its effectiveness after long-term use?

Official regulatory guidelines recommend that continuous therapy with Bemetson be duration-limited, typically to no more than two consecutive weeks. This short treatment period is established to mitigate both the risk of long-term side effects and potential concerns regarding reduced effectiveness over time.


Q: Is Bemetson classified as a controlled substance?

No, Bemetson (Betamethasone Dipropionate) is not classified as a controlled substance under the U.S. Controlled Substances Act or comparable international regulatory frameworks.


Q: Where can I find the complete regulatory prescribing information for Bemetson?

The complete and detailed regulatory information is made available in the official Prescribing Information documents. These include the FDA Label (in the US) or the Summary of Product Characteristics (SmPC) (in the EU/UK), and can typically be located on the respective national regulatory authority's website.


Q: Have there been any major safety alerts or recalls related to Bemetson in recent years?

Official regulatory bodies actively monitor drug safety through programs like the FDA MedWatch. A review of public databases does not indicate any major safety alerts or product recalls issued for Bemetson (Betamethasone Dipropionate) in recent years.


Q: Why is Bemetson sometimes prescribed alongside other medications?

Bemetson may be used as part of an intentional combination therapy, often in a single combined product. This is done when a condition requires both the powerful anti-inflammatory action of the corticosteroid and the treatment of a co-existing condition, such as a fungal or bacterial infection.


Q: What is the difference in safety profile between brand-name Bemetson and its generic version?

Generic formulations of Bemetson (Betamethasone Dipropionate) must meet regulatory standards for pharmaceutical equivalence to the brand-name product. Consequently, the generic version is required to carry the exact same safety warnings, precautions, and adverse event profile as the reference product.


Q: Why do some people experience dizziness when they first start taking Bemetson?

Dizziness is listed in the official documents as a possible, though uncommon, reported adverse reaction. In rare instances, this could be a sign of systemic absorption of the corticosteroid into the bloodstream or a potential sign of an allergic reaction. This reaction should be discussed with a healthcare professional.


Q: Can Bemetson be associated with a risk of dependence or addiction?

Bemetson is not considered a controlled substance and is not associated with a risk of abuse or addiction. However, prolonged or improper use can lead to physiological dependence, specifically HPA axis suppression, which means the medication may need to be stopped under medical supervision.

How should Bemetson be stored and disposed of?

Storage and Protection Requirements

Bemetson (Betamethasone Dipropionate) must be stored at controlled room temperature, typically maintained between 20 C and 25 C (68 F and 77 F). The product must be kept from freezing and protected from excessive heat and moisture. It is mandatory to store the medicine in the tightly closed container it came in and keep it out of the reach of children.

Stability and Disposal

To ensure stability, the product must be protected from light. For some formulations, a specific in-use period applies, such as discarding the tube after 28 days of first opening. Disposal of unused or expired Bemetson should follow established procedures. The FDA recommends using a drug take-back program; otherwise, the medicine should be mixed with an undesirable substance before being discarded in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bemetson found in:

A-Z Index: